MARC record from Internet Archive

LEADER: 06529cam 2200877Ia 4500
001 ocn299152535
003 OCoLC
005 20220730205402.0
008 090123s2008 nyuaf ob 001 0 eng d
006 m o d
007 cr cnu---unuuu
040 $aN$T$beng$epn$cN$T$dOCLCQ$dYDXCP$dIDEBK$dOCLCQ$dOCLCF$dOCLCA$dNLGGC$dAU@$dOCLCQ$dD6H$dCOCUF$dAGLDB$dOCLCO$dJBG$dOCLCO$dOCLCA$dU3W$dOCLCA$dSTF$dVNS$dOCLCO$dOCLCQ$dVTS$dOCLCO$dNLE$dOCLCO$dVT2$dTOF$dOCLCO$dOCLCQ$dOCLCO$dUKMGB$dOCLCO$dWYU$dTKN$dREC$dOCLCQ$dM8D$dOCLCO$dOCLCA$dOCLCO
016 7 $a014101299$2Uk
016 7 $a017596573$2Uk
019 $a842267696
020 $a9780080554952$q(electronic bk.)
020 $a0080554954$q(electronic bk.)
020 $a9780123694485
020 $a0123694485
035 $a(OCoLC)299152535$z(OCoLC)842267696
037 $a9780080554952$bIngram Content Group
050 4 $aRS431.A64$bC36 2008eb
060 4 $a2008 A-287
060 4 $aQV 269$bN397c 2008
072 7 $aMED$x062000$2bisacsh
072 7 $aHEA$x039030$2bisacsh
082 04 $a616.994061$222
245 00 $aCancer drug design and discovery /$cedited by Stephen Neidle.
250 $a1st ed.
260 $aNew York :$bAcademic Press,$c©2008.
300 $a1 online resource (xv, 473 pages, 27 unnumbered pages of plates) :$billustrations (some color)
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
504 $aIncludes bibliographical references and index.
505 0 $aModern cancer drug discovery : integrating targets, technologies and treatments / Paul Workman and Ian Collins -- Preclinical pharmacology and in vivo models / Lloyd Kelland -- Clinical trial designs for more rapid proof-of-principle and approval / Mitesh J. Borad and Daniel D. Van Hoff -- Structural biology and anticancer drug design / Dominic Tisi [and others] -- Natural product chemistry and anticancer drug discovery / Donna M. Huryn and Peter Wipf -- Pharmacokinetics and ADME optimization in drug discovery / Chad L. Stoner, Matthew D. Troutman and Caroline E. Laverty -- Temozolomide : from cytotoxic to molecularly-targeted agent / Malcolm F.G. Stevens -- Camptothecins for drug design, cancer cell death and gene targeting / Jérôme Kluza [and others] -- Targeting thymidylate synthase by antifolate drugs for the treatment of cancer / Ann L. Jackman, Martin Forster and Matthew Ng -- Targeting inactive kinases : structure as a foundation for cancer drug discovery / David J. Hosfield and Clifford D. Mol -- Cell cycle inhibitors in cancer : current status and future directions / Peter M. Fischer -- Inhibition of DNA repair as a therapeutic target / Nicola J. Curtin and Thomas Helleday -- HSP90 inhibitors : targeting the cancer chaperone for combinatorial blockade of oncogenic pathways / Swee Y. Sharp, Keith Jones and Paul Workman -- Heat shock protein-90 directed therapeutics and target validation / Edward A. Sausville -- Inhibitors of tumor angiogenesis / Adrian L. Harris and Daniele G. Generali -- The biology and oncology of RAF-ERK signaling / Victoria Emuss and Richard Marais -- Cancer drug resistance / V. Karavasilis [and others] -- Failure modes in anticancer drug discovery and development / Homer L. Pearce, Kerry L. Blanchard and Christopher A. Slapak.
588 0 $aPrint version record.
520 $aThe ultimate source of information on the design of new anticancer agents, emphasising small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumours. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry, and clinicians taking oncology options. * Covers both currently available drugs as well as those under development * Provides a clinical perspective on trials of new anticancer agents * Presents drug discovery examples through the use of case histories.
650 0 $aAntineoplastic agents$xDevelopment.
650 0 $aAntineoplastic agents$xDesign.
650 0 $aCancer$xChemotherapy.
650 0 $aAntimitotic agents.
650 0 $aAntineoplastic agents.
650 0 $aDrugs$xDesign.
650 12 $aAntineoplastic Agents
650 22 $aDrug Design
650 22 $aNeoplasms$xdrug therapy
650 2 $aAntimitotic Agents
650 6 $aCancer$xChimiothérapie.
650 6 $aAnticancéreux.
650 6 $aMédicaments$xConception.
650 7 $aMEDICAL$xOncology.$2bisacsh
650 7 $aHEALTH & FITNESS$xDiseases$xCancer.$2bisacsh
650 7 $aAntineoplastic agents$xDesign.$2fast$0(OCoLC)fst00810598
650 7 $aAntineoplastic agents$xDevelopment.$2fast$0(OCoLC)fst00810599
650 7 $aCancer$xChemotherapy.$2fast$0(OCoLC)fst00845327
655 0 $aElectronic books.
655 4 $aElectronic books.
700 1 $aNeidle, Stephen.$4edt
776 08 $iPrint version:$tCancer drug design and discovery.$b1st ed.$dNew York : Academic Press, ©2008$z9780123694485$z0123694485$w(OCoLC)154760280
856 40 $3EBSCOhost$uhttp://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=239287
856 40 $3MyiLibrary$uhttp://www.myilibrary.com?id=176368
856 40 $3ProQuest Ebook Central$uhttp://public.ebookcentral.proquest.com/choice/publicfullrecord.aspx?p=403943
856 40 $uhttps://nls.ldls.org.uk/welcome.html?ark:/81055/vdc_100026617853.0x000001$zView item
856 40 $zVIEW FULL TEXT$uhttp://VH7QX3XE2P.search.serialssolutions.com/?V=1.0&L=VH7QX3XE2P&S=JCs&C=TC0000117289&T=marc&tab=BOOKS
856 40 $3EBSCOhost$uhttp://er.llcc.edu:2048/login?url=http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=239287$yClick here for LLCC access.
938 $aEBSCOhost$bEBSC$n239287
938 $aYBP Library Services$bYANK$n2947837
029 1 $aAU@$b000050896175
029 1 $aAU@$b000051555928
029 1 $aDEBBG$bBV043158102
029 1 $aDEBSZ$b422087041
029 1 $aGBVCP$b802759815
029 1 $aUKMGB$b017596573
994 $aZ0$bIME
948 $hNO HOLDINGS IN IME - 1252 OTHER HOLDINGS